Peer-Reviewed Journal Details
Mandatory Fields
O'Mahony, AM,Doyle, D,Darcy, R,Cryan, JF,O'Driscoll, CM
2012
January
European Journal of Pharmaceutical Sciences
Characterisation of cationic amphiphilic cyclodextrins for neuronal delivery of siRNA: Effect of reversing primary and secondary face modifications
Validated
()
Optional Fields
Modified cyclodextrins siRNA delivery Neurons Low-toxicity SMALL INTERFERING RNA GENE DELIVERY BETA-CYCLODEXTRIN NERVOUS-SYSTEM TARGETED GENE TRANSFECTION NANOPARTICLES TRAFFICKING CHEMISTRY VECTORS
47
896
903
Significant research is focused on the development of non-viral vectors for delivery of siRNA to neurons and the central nervous system. Cyclodextrins (CDs) have shown great promise as efficient and low toxicity gene delivery vectors in various cell types. Here, we investigate two CDs for siRNA delivery in a neuronal cell model. These CDs were substituted on opposite faces (primary and secondary) with amphiphilic and cationic groups.Physical properties of CD.siRNA complexes, including size, charge and stability were measured. In vitro investigations were carried out in immortalised hypothalamic neurons. Neuronal cell uptake was measured by flow cytometry and cytotoxicity was assessed by MTT assay. Knockdown of a luciferase reporter gene was used as a measure of gene silencing efficiency.Both CDs interacted with siRNA, yielding nanosized cationic complexes which exhibited good stability on storage. A favourable toxicity profile was demonstrated for the CD.siRNA complexes. However, only one of the two CDs mediated high levels of neuronal uptake and efficient gene silencing, equivalent to those achieved with a commercial lipid-based vector.Despite the suitability of both CDs as siRNA delivery vectors in terms of their ability to complex siRNA and the properties of the complexes yielded, only one CD achieved good transfection efficiency. This was likely due to the differences in their chemical structures. The effective CD offers great potential as a novel non-toxic vector for neuronal siRNA delivery. (C) 2012 Elsevier B.V. All rights reserved.
DOI 10.1016/j.ejps.2012.08.020
Grant Details